Balversa (erdafitinib tablets – Janssen) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has locally advanced or metastatic disease
• Patient has susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations
• Patient has progressed during or following prior platinum-containing chemotherapy, other chemotherapy, or checkpoint inhibitor therapy
• Medication is used as a single agent

Approval duration

1 year